Clinical Research Supportive Care

Providing our patients with supportive care is a cornerstone of Comprehensive Cancer Centers’s clinical research studies.

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Doses of a Vaccine Based Immunotherapy Regimen (VBIR) (PF-06753512) in Patients with Prostate Cancer
Study #: i2190
Local P.I.: Dr. Nicholas Voglezang Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

Phase 1, Open‑Label, dose escalation and expansion study of PF‑06801591 in patients with locally advanced or metastatic melanoma, squamous cell head and neck cancer, ovarian cancer, Sarcoma, OR relapsed or refractory Classic Hodgkin Lymphoma
Study #: i2198
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications *Call Project Manager*
Study #: 15239
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects with Advanced Non-small Cell Lung Cancer **Current Slot Availability- Track 1.a.: 13 slots; Track 1.b.: 46 slots, Track 2: 33 slots, Track 3- HOLDING ALL ENROLLMENT (Waitlist Available), Track 4- 91 slots, and Track 5- HOLDING ENROLLMENT
Study #: 15183
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) **ON HOLD*
Study #: i2376
Local P.I.: Dr. Nicholas Voglezang Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other B7-H3-Expressing Cancers
Study #: i2417
Local P.I.: Dr. Nicholas Voglezang Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial
Study #: i2420
Cancer and Other Malignant Solid Tumors that Express Nectin-4″
Local P.I.: Dr. Nicholas Voglezang Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies **ON SPONSOR HOLD**
Study #: i2383
Local P.I.: Dr. Nicholas Voglezang Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects with Advanced or Metastatic Solid Tumors **ON SPONSOR HOLD**”
Study #: i2381
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

Phase I of AZD6244 & Medi4736 in Solids An Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination with MEDI4736 and Selumetinib in Combination with MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumors
Study #: i2409
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Advanced Solid Tumor Malignancies
Study #: i2439
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
Study #: i2410
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma **ON HOLD**
Study #: i2476
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

Phase Ia/Ib Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of Ro7198457 As A Single Agent And In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Tumors
Study #: i2473
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Study #: i2459
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

An Open-Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech And/Or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Study #: 17087
Local P.I.: Dr. Nicholas Voglezang Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

Idasanutlin w/rand. single dose A Multi-Center, Open-Label, Clinical Pharmacology Study For idasanutlin, An Mdm2 Antagonist With A Hybrid Randomized/Sequential, Single Dose, 4-Period Crossover Design To Investigate The Bioequivalence Or Relative Bioavailability Of Three New Idasanutlin Tablet Variants Following Oral Administration In Patients With Solid Tumors
Study #: i2495
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 In Adult Patients With Advanced Malignancies **ON HOLD**
Study #: i2487
Local P.I.: Dr. Fadi Braiteh Sites: Twain
Contact Us: For information about this clinical study, Email Us, or use our form field